Role of substance P in blood pressure regulation in salt-dependent experimental hypertension

Hypertension

Volumn 29, Issue 1 II, 1997, Pages 506-509

  Kohlmann Jr , Osvaldo ^a   Cesaretti, Mario Luis ^b   Ginoza, Milton ^b   Tavares, Agostinho ^b   Zanella, Maria Teresa ^b   Ribeiro, Artur Beltrame ^b   Ramos, Oswaldo Luiz ^b   Leeman, Susan E ^b   Gavras, Irene ^b   Gavras, Haralambos ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

experimental hypertension; receptors NK 1; sodium dependent hypertension; substance P; tachykinins

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; NEUROKININ 1 RECEPTOR ANTAGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HEART RATE; MALE; NONHUMAN; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; PROTEIN FAMILY; RAT; SALT INTAKE; VASOCONSTRICTION;

EID: 0031032201     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.29.1.506     Document Type: Article

References (20)

1. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993;73:229-308.
2. Gilles RA, Helke CJ, Hamilton NL, Norman WP, Jacobowitz DM. Evidence that substance P is a neurotransmitter of baro- and chemoreceptor afferents in nucleus tractus solitarius. Brain Res. 1980; 181:476-481.
3. Benarroch EE. Neuropeptides in the sympathetic system: presence, plasticity, modulation and implications. Ann Neurol. 1994;36:6-13.
4. Ekstrom J, Hakanson R, Mansson B, Tobin G. Tachykinin involvement in parasympathetic nerve-evoked salivation of the ferret. Br J Pharmacol. 1988;94:707-712.
5. Pernow B, Rosell S. Effect of substance P on blood flow in canine adipose tissue and skeletal muscle. Acta Physiol Scand. 1975;93: 139-141.
6. Halberg D, Pemow B. Effect of substance P on various vascular beds in the dog. Acta Physiol Scand. 1975;93:277-285.
7. Burcher E, Atterhog JH, Pemow B, Rossel S. Cardiovascular effects of substance P: effects on heart and regional blood flow in the dog. In: von Euler US, Pernow B, eds. Substance P. New York, NY: Raven Press; 1977:261-269.
8. Stewart-Lee A, Bumstock G. Actions of tachykinins on the rabbit mesenteric artery: substance P and [Glp6-L-Pro9] SP6-11 are potent agonists for endothelial neurokinin-1 receptors. Br J Pharmacol. 1989;97:1218-1224.
9. Whittle BJR, Lopez-Belmont J, Press DD. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol. 1989;98:646-652.
10. D'Orleans-Juste P, Dion S, Drapeau G, Regoli D. Different receptors are involved in the endothelium-mediated relaxation and the smooth muscle contraction of the rabbit pulmonary artery response to substance P and related neurokinins. Eur J Pharmacol. 1986;125:37-44.
11. Mastrangelo D, Mathison R, Huggel HG, Dion S, D'Orleans-Juste P, Rhaleb NE, Drapeu G, Rovero P, Regoli D. The rat isolated portal vein: a preparation sensitive to neurokinin particularly neurokinin B. Eur J Pharmacol. 1987;134:321-326.
12. Couture R, Regoli D. Mini-review: smooth muscle pharmacology of substance P. Pharmacology. 1982;24:1-25.
13. Mori K, Asakura S, Ogawa H, Sagagawa S, Takeyama M. Decreases in substance P and vasoactive peptide concentrations in plasma of stroke-prone spontaneously hypertensive rats. Jpn Heart J. 1993; 34:785-794.
14. Faulhaber HD, Rathsack R, Rostock G, Homuth V, Pfeiffer D, Naumann E, Hartrodt W, Gorme RC, Oehme P. Evidence of decreased plasma substance P levels in human essential hypertension and influence of prazosin treatment. Biomed Biochim Acta. 1983:7/8: 1019-1025.
15. Martin G, Urmantcheeva TG, Wolter F, Gurck Colditz M, Stechmesser G, Faulhaber HD. Neurophysiological effects of substance P in primate hypertension models. Cor Vasa. 1990;32:484-491.
16. Unger T, Carolus S, Demmert G, Ganten D, Lang RE, Maser-Gluth C, Steinberg H, Veelken R. Substance P induces a cardiovascular defense reaction in the rat: pharmacology characterization. Circ Res. 1988;63:812-820.
17. Snider RM, Constantine JW, Lowe JA III, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinik FJ, Spencer RW, Hess HJ. A potent nonpeptide antagonist of substance P (NK-1) receptor. Science. 1991;251:435-437.
18. Mclean S, Ganong AH, Seeger TF, Bryce DK, Pratt KG, Reynolds LS, Stock CJ, Lowe JA III, Heym J. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK-1) receptor antagonist. Science. 1991;251:437-439.
19. Kohlmann O Jr, Ginoza M, Cesaretti ML, Zanella MT, Ribeiro AB, Tavares A, Ramos OL, Leeman SE, Gavras I, Gavras H. Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in DOCA-salt hypertension. Hypertension. 1995; 26(part 2):1186-1189.
20. Kohlmann O Jr, Ginoza M, Cesaretti ML, Zanela MT, Ribeiro AB, Tavares A, Leeman SE, Gavras I, Gavras H. Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in experimental hypertension. Hypertension. 1995;26:557. Abstract.